.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AX26_Amenamevir.Amenamevir .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AX26_Amenamevir.Amenamevir| name: | Amenamevir | |
| ATC code: | J05AX26 | |
| route: | oral | |
| compartments: | 2 | |
| dosage: | 400 | mg |
| volume of distribution: | 139 | L |
| clearance: | 15.0 | L/h |
| other parameters in model implementation | ||
Amenamevir is an orally active helicase-primase inhibitor used for the treatment of herpes zoster (shingles) in adults. It is approved and marketed in Japan for this indication. Amenamevir inhibits the helicase-primase complex essential for herpesvirus DNA replication.
Pharmacokinetic parameters reported for healthy adult Japanese volunteers receiving single oral doses of amenamevir.